Glucocorticoids and the Th1/Th2 balance

Annals of the New York Academy of Sciences

Volumn 1024, Issue , 2004, Pages 138-146

  Elenkov, Ilia J ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Allergy; Autoimmunity; Glucocorticoids; Inflammation; Interleukin 10; Interleukin 12; Multiple sclerosis; Rheumatoid arthritis; Stress; Th1 cells; Th2 cells

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 12; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC DISEASE; ANTIGEN PRESENTING CELL; ATOPY; AUTOIMMUNE DISEASE; CELL SECRETION; CELLULAR IMMUNITY; CONFERENCE PAPER; CYTOKINE PRODUCTION; DRUG MECHANISM; EXERCISE; HELPER CELL; HORMONE ACTION; HUMAN; HUMORAL IMMUNE DEFICIENCY; HUMORAL IMMUNITY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION SENSITIVITY; INFLAMMATION; LYMPHOCYTE FUNCTION; MACROPHAGE ACTIVATION; NONHUMAN; PREGNANCY; PROTEIN SECRETION; PUERPERAL DEPRESSION; STRESS; TH1 CELL; TH2 CELL;

EID: 3042749817     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1321.010     Document Type: Conference Paper

References (60)

1. MOSMANN, T.R. & S. SAD. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17: 138-146.
2. FEARON, D.T. & R.M. LOCKSLEY. 1996. The instructive role of innate immunity in the acquired immune response. Science 272: 50-53.
3. TRINCHIERI, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3: 133-146.
4. ELENKOV, I.J. & G.P. CHROUSOS. 1999. Stress hormones, Th1/Th2 patterns, pro/antiinflammatory cytokines and susceptibility to disease. Trends Endocrinol. Metab. 10: 359-368.
5. CHROUSOS, G.P. 1995. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation [see comments]. N. Engl. J. Med. 332: 1351-1362.
6. WILDER, R.L. 1995. Neuroendocrine-immune system interactions and autoimmunity. Annu. Rev. Immunol. 13: 307-338.
7. LERNER, B.H. 1996. Can stress cause disease? Revisiting the tuberculosis research of Thomas Holmes, 1949-1961. Ann. Intern. Med. 124: 673-680.
8. VON HERTZEN, L.C. 2002. Maternal stress and T-cell differentiation of the developing immune system: possible implications for the development of asthma and atopy. J. Allergy Clin. Immunol. 109: 923-928.
9. ELENKOV, I.J., R.L. WILDER, V.K. BAKALOV, et al. 2001. IL-12, TNF-alpha, and hormonal changes during late pregnancy and early postpartum: implications for autoimmune disease activity during these times. J. Clin. Endocrinol. Metab. 86: 4933-4938.
10. BEUTLER, B., N. KROCHIN, I.W. MILSARK, et al. 1986. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 232: 977-980.
11. BOUMPAS, D.T., G.P. CHROUSOS, R.L. WILDER, et al. 1993. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann. Intern. Med. 119: 1198-1208.
12. ELENKOV, I.J., D.A. PAPANICOLAOU, R.L. WILDER & G.P. CHROUSOS. 1996. Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications. Proc. Assoc. Am. Physicians. 108: 374-381.
13. BLOTTA, M.H., R.H. DEKRUYFF & D.T. UMETSU. 1997. Corticosteroids inhibit IL-12 production in human monocytes and enhance their capacity to induce IL-4 synthesis in CD4+ lymphocytes. J. Immunol. 158: 5589-5595.
14. DEKRUYFF, R.H., Y. FANG & D.T. UMETSU. 1998. Corticosteroids enhance the capacity of macrophages to induce Th2 cytokine synthesis in CD4+ lymphocytes by inhibiting IL-12 production. J. Immunol. 160: 2231-2237.
15. WU, C.Y., K. WANG, J.F. MCDYER & R.A. SEDER. 1998. Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness. J. Immunol. 161: 2723-2730.
16. KODAMA, M., H.K. TAKAHASHI, H. IWAGAKI, et al. 2002. Effect of steroids on lipopolysaccharide/interleukin 2-induced interleukin 18 production in peripheral blood mononuclear cells. J. Int. Med. Res. 30: 144-160.
17. MYSLIWIEC, J., A. KRETOWSKI, A. STEPIEN, et al. 2003. Interleukin 18 and transforming growth factor beta1 in the serum of patients with Graves' ophthalmopathy treated with corticosteroids. Int. Immunopharmacol. 3: 549-552.
18. REISSLAND, P. & K.P. WANDINGER. 1999. Increased cortisol levels in human umbilical cord blood inhibit interferon alpha production of neonates. Immunobiology 200: 227-233.
19. RAMIERZ, F., D.J. FOWELL, M. PUKLAVEC, et al. 1996. Glucocorticoids promote a TH2 cytokine response by CD4+ T cells in vitro. J. Immunol. 156: 2406-2412.
20. VAN DER POLL, T., A.E. BARBER, S.M. COYLE & S.F. LOWRY. 1996. Hypercortisolemia increases plasma interleukin-10 concentrations during human endotoxemia - a clinical research center study. J. Clin. Endocrinol. Metab. 81: 3604-3606.
21. SHADIACK, A.M., C.D. CARLSON, M. DING, et al. Lipopolysaccharide induces substance P in sympathetic ganglia via ganglionic interleukin-1 production. J. Neuroimmunol. 49: 51-58.
22. TABARDEL, Y., J. DUCHATEAU, D. SCHMARTZ, et al. 1996. Corticosteroids increase blood interleukin-10 levels during cardiopulmonary bypass in men. Surgery 119: 76-80.
23. GAYO, A., L. MOZO, A. SUAREZ, et al. 1998. Glucocorticoids increase IL-10 expression in multiple sclerosis patients with acute relapse. J. Neuroimmunol. 85: 122-130.
24. NASEER, T., E.M. MINSHALL, D.Y. LEUNG, et al. 1997. Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy. Am. J. Respir. Crit. Care Med. 155: 845-851.
25. BENTLEY, A.M., Q. HAMID, D.S. ROBINSON, et al. 1996. Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am. J. Respir. Crit. Care Med. 153: 551-556.
26. BRADDING, P., I.H. FEATHER, S. WILSON, et al. 1995. Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteroid. Am. J. Respir. Crit. Care Med. 151: 1900-1906.
27. BATUMAN, O.A., A. FERRERO, C. CUPP, et al. 1995. Differential regulation of transforming growth factor beta-1 gene expression by glucocorticoids in human T and glial cells. J. Immunol. 155: 4397-4405.
28. BROUG-HOLUB, E. & G. KRAAL. 1996. Dose- and time-dependent activation of rat alveolar macrophages by glucocorticoids. Clin. Exp. Immunol. 104: 332-336.
29. MOLLER, B., N. KUKOC-ZIVOJNOV, N. KOYAMA, et al. 2002. Prednisolone induces interleukin-18 expression in mononuclear blood and myeloid progenitor cells. Inflamm. Res. 51: 457-463.
30. KRISTO, C., K. GODANG, T. UELAND, et al. 2002. Raised serum levels of interleukin-8 and interleukin-18 in relation to bone metabolism in endogenous Cushing's syndrome. Eur. J. Endocrinol. 146: 389-395.
31. KARALIS, K., H. SANO, J. REDWINE, et al. 1991. Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science 254: 421-423.
32. ELENKOV, I.J., E.L. WEBSTER, D.J. TORPY & G.P. CHROUSOS. 1999. Stress, corticotropin-releasing hormone, glucocorticoids, and the immune/inflammatory response: acute and chronic effects. Ann. N.Y Acad. Sci. 876: 1-11.
33. THEOHARIDES, T.C., L.K. SINGH, W. BOUCHER, et al. 1998. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology 139: 403-413.
34. FOREMAN, J.C. 1987. Substance P and calcitonin gene-related peptide: effects on mast cells and in human skin. Int. Arch. Allergy Appl. Immunol. 82: 366-371.
35. CHURCH, M.K., M.A. LOWMAN, C. ROBINSON, et al. 1989. Interaction of neuropeptides with human mast cells. Int. Arch. Allergy Appl. Immunol. 88: 70-78.
36. ROZNIECKI, J.J., E. WEBSTER & G.P. CHROUSOS. 1995. Stress-induced intracranial mast cell degranulation: a corticotropin-releasing hormone-mediated effect. Endocrinology 136: 5745-5750.
37. ELENKOV, I.J., R.L. WILDER, G.P. CHROUSOS & E.S. VIZI. 2000. The sympathetic nerve - an integrative interface between two supersystems: the brain and the immune system. Pharmacol. Rev. 52: 595-638.
38. ALTARE, F., A. DURANDY, D. LAMMAS, et al. 1998. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 280: 1432-1435.
39. LEVENSTEIN, S. 1998. Stress and peptic ulcer: life beyond Helicobacter. Brit. Med. J. 316: 538-541.
40. LEVENSTEIN, S., S. ACKERMAN, J.K. KIECOLT-GLASER & A. DUBOIS. 1999. Stress and peptic ulcer disease. J. Am. Med. Assoc. 281: 10-11.
41. CLERICI, M., M. BEVILACQUA, T. VAGO, et al. 1994. An immunoendocrinological hypothesis of HIV infection [see comments]. Lancet 343: 1552-1553.
42. KINO, T., A. GRAGEROV, J.B. KOPP, et al. 1999. The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor. [In Process Citation] J. Exp. Med. 189: 51-62.
43. MIRANI, M., I. ELENKOV, S. VOLPI, et al. 2002. HIV-1 protein Vpr suppresses IL-12 production from human monocytes by enhancing glucocorticoid action: potential implications of Vpr coactivator activity for the innate and cellular immunity deficits observed in HIV-1 infection. J. Immunol. 169: 6361-6368.
44. COHEN, S., D.A. TYRRELL & A.P. SMITH. 1991. Psychological stress and susceptibility to the common cold [see comments]. N. Engl. J. Med. 325: 606-612.
45. SAINZ, B., J.M. LOUTSCH, M.E. MARQUART & J.M. HILL. 2001. Stress-associated immunomodulation and herpes simplex virus infections. Med. Hypotheses 56: 348-356.
46. HUMBERT, M., G. MENZ, S. YING, et al. 1999. The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. Immunol. Today 20: 528-533.
47. WILLS-KARP, M. 2001. IL-12/IL-13 axis in allergic asthma. J. Allergy Clin. Immunol. 107: 9-18.
48. MARSHALL, G.D., JR. & S.K. AGARWAL. 2000. Stress, immune regulation, and immunity: applications for asthma. Allergy Asthma Proc. 21: 241-246.
49. VON HERTZEN, L.C. 2002. Maternal stress and T-cell differentiation of the developing immune system: possible implications for the development of asthma and atopy. J. Allergy Clin. Immunol. 109: 923-928.
50. BARNES, P., G. FITZGERALD, M. BROWN & C. DOLLERY. 1980. Nocturnal asthma and changes in circulating epinephrine, histamine, and cortisol. N. Engl. J. Med. 303: 263-267.
51. PANINA-BORDIGNON, P., D. MAZZEO, P.D. LUCIA, et al. 1997. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J. Clin. Invest. 100: 1513-1519.
52. ZIEG, G., G. LACK, R.J. HARBECK, et al. 1994. In vivo effects of glucocorticoids on IgE production [see comments]. J. Allergy Clin. Immunol. 94: 222-230.
53. COQUERET, O., V. LAGENTE, C.P. FRERE, et al. 1994. Regulation of IgE production by beta 2-adrenoceptor agonists. Ann. N.Y. Acad. Sci. 725: 44-49.
54. SEGAL, B.M., B.K. DWYER & E.M. SHEVACH. 1998. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J. Exp. Med. 187: 537-546.
55. STERNBERG, E.M. 2001. Neuroendocrine regulation of autoimmune/ inflammatory disease. J. Endocrinol. 169: 429-435.
56. ELENKOV, I.J. & G.P. CHROUSOS. 2002. Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. Ann. N.Y. Acad. Sci. 966: 290-303.
57. STERNBERG, E.M., W.S. YOUNG, R. BERNARDINI, et al. 1989. A central nervous system defect in biosynthesis of corticotropin-releasing hormone is associated with susceptibility to streptococcal cell wall-induced arthritis in Lewis rats. Proc. Natl. Acad. Sci. USA 86: 4771-4775.
58. STERNBERG, E.M., J.M. HILL, G.P. CHROUSOS, et al. 1989. Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats. Proc. Natl. Acad. Sci. USA 86: 2374-2378.
59. WILDER, R.L. & I.J. ELENKOV. 1999. Hormonal regulation of tumor necrosis factor-alpha, interleukin-12 and interleukin-10 production by activated macrophages. A disease-modifying mechanism in rheumatoid arthritis and systemic lupus erythematosus? Ann. N.Y. Acad. Sci. 876: 14-31.
60. STRAUB, R.H. & M. CUTOLO. 2001. Involvement of the hypothalamic-pituitary-adrenal/gonadal axis and the peripheral nervous system in rheumatoid arthritis: viewpoint based on a systemic pathogenetic role. Arthritis Rheum. 44: 493-507.